Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Thursday, April 2, 2015, 86 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $348.46 to $37,984,375.00.

Highlighted Stocks Traded by Insiders:

National Health Investors (NHI) - FREE Research Report

Hutchens James Justin, who is CEO and President at National Health Investors, sold 5,950 shares at $70.26 on April 2, 2015. Following this transaction, the CEO and President owned 67,419 shares meaning that the stake was reduced by 8.11% with the 5,950-share transaction.

The shares most recently traded at $72.46, up $2.20, or 3.04% since the insider transaction. Historical insider transactions for National Health Investors go as follows:

  • 4-Week # shares bought: 398
  • 4-Week # shares sold: 5,950
  • 12-Week # shares bought: 398
  • 12-Week # shares sold: 5,950
  • 24-Week # shares bought: 398
  • 24-Week # shares sold: 5,950

The average volume for National Health Investors has been 197,900 shares per day over the past 30 days. National Health Investors has a market cap of $2.7 billion and is part of the financial sector and real estate industry. Shares are up 2.3% year-to-date as of the close of trading on Thursday.

National Health Investors Inc. is a real estate investment trust. It invests in the real estate markets of United States. The firm invests in the health care properties primarily in the long-term care and senior housing industries. The stock currently has a dividend yield of 4.75%. The company has a P/E ratio of 23.5. Currently, there is 1 analyst who rates National Health Investors a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NHI - FREE

TheStreet Quant Ratings

rates National Health Investors as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full

National Health Investors Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

New York & Company (NWY) - FREE Research Report

Scott Gregory J, who is Chief Executive Officer at New York & Company, bought 10,000 shares at $2.52 on April 2, 2015. Following this transaction, the Chief Executive Officer owned 640,000 shares meaning that the stake was boosted by 1.59% with the 10,000-share transaction.

Worthington John M, who is President and COO at New York & Company, bought 12,500 shares at $2.52 on April 2, 2015. Following this transaction, the President and COO owned 262,500 shares meaning that the stake was boosted by 5% with the 12,500-share transaction.

The shares most recently traded at $2.92, up $0.40, or 13.7% since the insider transaction. Historical insider transactions for New York & Company go as follows:

  • 4-Week # shares bought: 34,500
  • 4-Week # shares sold: 47,272
  • 12-Week # shares bought: 34,500
  • 12-Week # shares sold: 47,272
  • 24-Week # shares bought: 34,500
  • 24-Week # shares sold: 47,272

The average volume for New York & Company has been 89,800 shares per day over the past 30 days. New York & Company has a market cap of $197.2 million and is part of the services sector and retail industry. Shares are up 16.29% year-to-date as of the close of trading on Thursday.

New York & Company, Inc., together with its subsidiaries, operates as a specialty retailer of women's fashion apparel and accessories in the United States. Currently, there are 2 analysts who rate New York & Company a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NWY - FREE

TheStreet Quant Ratings

rates New York & Company as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, poor profit margins, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full

New York & Company Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Cyberonics (CYBX) - FREE Research Report

Browne Gregory H, who is SR VP Finance & CFO at Cyberonics, sold 2,000 shares at $64.63 on April 2, 2015. Following this transaction, the SR VP Finance & CFO owned 53,716 shares meaning that the stake was reduced by 3.59% with the 2,000-share transaction.

Wise David S, who is SR VP & Chief Admin Officer at Cyberonics, sold 2,000 shares at $64.43 on April 2, 2015. Following this transaction, the SR VP & Chief Admin Officer owned 53,007 shares meaning that the stake was reduced by 3.64% with the 2,000-share transaction.

The shares most recently traded at $64.76, up $0.33, or 0.51% since the insider transaction. Historical insider transactions for Cyberonics go as follows:

  • 4-Week # shares sold: 6,735
  • 12-Week # shares sold: 17,970
  • 24-Week # shares sold: 36,865

The average volume for Cyberonics has been 553,600 shares per day over the past 30 days. Cyberonics has a market cap of $1.7 billion and is part of the health care sector and health services industry. Shares are up 17.65% year-to-date as of the close of trading on Thursday.

Cyberonics, Inc., together with its subsidiaries, designs, develops, markets, and sells implantable medical devices to hospitals and ambulatory surgery centers. The company has a P/E ratio of 26.5. Currently, there are 3 analysts who rate Cyberonics a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CYBX - FREE

TheStreet Quant Ratings

rates Cyberonics as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Cyberonics Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null